spacer
home > pmps > summer 2019 > staying ahead of the curve
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Staying Ahead of the Curve

In the grand scheme of clinical trial planning, labelling processes may seem insignificant in comparison to obvious fundamentals such as drug manufacturing, securing funding, or patient recruitment. As clinical packaging is typically approached sequentially (manufacture, package, label, ship), it is unsurprising that labelling is usually only properly considered and defined during the latter stages of the process. It is just a label after all, right?

Wrong. A label is the first thing a patient – and a regulator – will see when they receive a kit. A label is also vital in the bid to obtain approval in countries where a trial is operating. With the American Journal of Health citing that incorrect labelling is one of the top five reasons for drug recall in the US, it is time we acknowledge the real role labelling plays in the bigger picture of a clinical trial’s success.

Clinical trials are changing rapidly, and this is having a big impact on labelling processes, which need to evolve to meet increasingly complex criteria. Labels are no longer used as a basic table of contents, but they need to be multifunctional and used to deliver variable information in different formats and languages. The core drivers for change can be grouped into four categories: the emergence of biologics products, growth in global trials, increased regulation, and adaptive trials − each bringing its own set of labelling challenges.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
James McAleavey graduated from Queen’s University Belfast, UK, with a BSc honours degree in Mathematics and Computer Science. James joined Almac Clinical Services in 2002, having previously worked within the labelling industry for almost 10 years. As part of Almac’s global label services team, he is a subject matter expert on the challenges of the regulatory and design aspects of labels within a clinical trial and the key role they play in ensuring successful study and patient compliance. He has extensive experience in the auditing of label manufacturing and packaging sites throughout the world, imparting knowledge on the regulatory requirements and industry expectations.
spacer
James McAleavey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

Event profile: PHARMAPACK 2020

6-7 February 2020,

Nemera will join more than 5,000 senior pharma professionals at Pharmapack, which will take place in Paris, on 5-6 February 2020. Meet Nemera at the booth C56 to discover its innovative drug delivery devices and its end-to-end development offerings! 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement